Evidence map›Paper›PMID 39470815›Full record

ArticleJournal of cancer research and clinical oncology2024

Dysregulation of SIGLEC1 in non-small cell lung cancer: prognostic implications and immunomodulatory role-a multicenter cohort study.

Yuan Liu, Wei Lin, Yang Gu, Chenlin Lu, Xuan Zhou, Hongyu Zhao, Gaoren Wang, Aiguo Shen

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuan Liu *Cancer Research Center Nantong, Affiliated Tumor Hospital of Nantong University, Nantong, 226006, China.
Wei Lin *Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China.
Yang Gu *Department of Clinical Medicine, General Medical Class 8, Kangda College of Nanjing Medical University, Lianyungang, 222000, China.
Chenlin LuDepartment of Respiratory and Critical Care Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 214504, China.
Xuan ZhouDepartment of Radiotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.
Hongyu ZhaoDepartment of Radiotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.
Gaoren WangCancer Research Center Nantong, Affiliated Tumor Hospital of Nantong University, Nantong, 226006, China. wanggaoren111@163.com.
Aiguo ShenCancer Research Center Nantong, Affiliated Tumor Hospital of Nantong University, Nantong, 226006, China. aiguoshen_nt@126.com.

Funding

National Natural Science Foundation of China 82402962the project of the Nantong Municipal Health Commission QN2022030
6 · The paper itself

Abstract

purposeTo investigate the clinical significance and functional role of SIGLEC1-positive cells in non-small cell lungcancer (NSCLC) patients, focusing on their prognostic impact and therapeutic response.

methodsA multicenter retrospective cohort analysis was conducted, integrating data from multiple sources. Weanalyzed SIGLEC1 expression in NSCLC tissues, clinicopathological features, overall survival outcomes,chemotherapy responsiveness, and sensitivity to targeted therapies. We also developed a prognostic model basedon SIGLEC1 expression and clinical variables.

resultsSIGLEC1 expression was significantly downregulated in NSCLC tissues, and the density of SIGLEC1-positivecells was inversely correlated with various clinicopathological features. Notably, patients with high infiltration ofSIGLEC1-positive cells exhibited significantly better overall survival outcomes. Furthermore, elevated SIGLEC1expression was associated with improved responsiveness to chemotherapy and demonstrated distinct patterns ofsensitivity to targeted therapies. A robust prognostic model was developed by integrating SIGLEC1 expression andclinical variables.

conclusionsThis study highlighted the downregulation of SIGLEC1 in NSCLC tissues and its significant associationwith patient prognosis and therapeutic response. The findings suggested that SIGLEC1 played a critical role inmodulating the tumor immune microenvironment and has potential as both a prognostic biomarker and therapeutictarget in NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSialic Acid Binding Ig-like Lectin 1AgedBiomarkers, TumorCohort StudiesFemaleHumansImmunomodulationMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorSialic Acid Binding Ig-like Lectin 1SIGLEC1 protein, humanImmune infiltrationNon-small cell lung cancerPrognosisSIGLEC1Therapy

Identifiers

PMID39470815
PMCPMC11522155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.